Showing results (131-140 of 357) with videos related to

Sort By:
Pageof 36
Journal for Immunotherapy of Cancer|October 9, 2025
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapyPaolo Strati, Amanda Brandt, Anath C Lionel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2019
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning RegimensHossein Maymani, Paul Lin, Rima M Saliba, et al.
Blood|May 15, 2010
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemiaFarhad Ravandi, Susan O'Brien, Deborah Thomas, et al.
American Journal of Hematology|April 23, 2009
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphomaChitra Hosing, Rima M Saliba, Sheena Ahlawat, et al.
American Journal of Hematology|April 30, 2014
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemiaOhad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 20, 2011
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenibManish Sharma, Farhad Ravandi, Ulas Darda Bayraktar, et al.
American Journal of Hematology|March 10, 2022
External validation of the HIGH-2-LOW model: A predictive score for venous thromboembolism after allogeneic transplantAng Li, Kylee L Martens, Daniel Nguyen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 3, 2010
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignanciesPartow Kebriaei, Timothy Madden, Reza Kazerooni, et al.
Cancer|March 22, 2017
Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioningOrhan Kemal Yucel, Rima M Saliba, Gabriella Rondon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 23, 2009
Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statementPaul J Martin, Carlos R Bachier, Hans-Georg Klingemann, et al.
Pageof 36